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Abstract: The conversion of Z-phenylalanine hydrazide with cyanogen bromide resulted 
in the formation of the corresponding 2-amino-1,3,4-oxadiazole by spontaneous cyclization 
of the intermediary cyanohydrazide. The molecular structure of the product was confirmed 
by single crystal X-ray diffraction. Crystals of the title compound where obtained from a 
saturated solution in a mixture of petroleum ether and ethyl acetate and belong to the 
monoclinic space group P21 with unit cell parameters a = 9.8152(2) Å, b = 9.6305(2) Å,  
c = 9.8465(2) Å, β = 116.785(1)°. The asymmetric unit contains one molecule. 
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1. Introduction 
The replacement of the α-carbon in peptides by a nitrogen atom leads to azapeptides imparting 
distinct conformational properties to the corresponding peptide chain [1]. This concept was recently 
applied to the C-terminal portion of dipeptide nitriles, an important chemotype of cysteine protease 
inhibitors [2], affording compounds that revealed higher inhibitory potency than their carbon-based 
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counterparts [3]. These amino acid-derived cyanohydrazides, also referred to as azadipeptide  
nitriles, attracted interest in medicinal chemistry-related research [4]. Notably, peptide derivatives 
incorporating internal azaglycine residues, the most simple aza-amino acid, are stable in their  
open-chain form. In contrast to this, the nitrogen analogues of dipeptides nitriles, as represented by 
cyanohydrazides derived from amino acids, are only existent if both nitrogen atoms are at least 
methylated [3]. N’-Cyano-N,N’-dimethylhydrazides can be obtained by reaction of the corresponding 
N,N’-dimethylhydrazides with cyanogen bromide. Contrary to that, conversion of unsubstituted 
hydrazides leads to 2-amino-1,3,4-oxadiazoles by spontaneous cyclization of the intermediary 
cyanohydrazides [5,6], even though open-chain N,N’-unsubstituted cyanohydrazides have been reported 
erroneously in the earlier literature [7]. 
The heteroaromatic 1,3,4-oxadiazole ring system for itself is considerably important in the field of 
biologically active molecules [8,9]. In addition, these heterocycles have attracted interest for materials 
chemistry as well, for example as benchmark electron-transport molecules in light-emitting devices [10]. 
The importance of 1,3,4-oxadiazoles is mainly due to their unique geometrical and electronic properties 
such as high dipole moment and their susceptibility to hydrogen bond contacts. Compared to their 
1,2,4-isomers, 1,3,4-oxadiazoles are characterized by a considerably higher dipole moment (1.8 D 
versus 3.1 D, respectively, for the unsubstituted heterocycles) and thus exhibit improved water 
solubility [9]. 
Due to its rather facile synthetic accessibility, the 1,3,4-oxadiazole system is employed in the design 
of constrained peptidomimetics [11,12]. 
Amino acid-derived 2-amino-1,3,4-oxadiazoles have been reported occasionally in the patent 
literature in the context of IB kinase inhibitors [13] and ligands of the cannabinoid receptor CB1 [14]. 
Furthermore, the synthesis of derivatives containing an additional amino acid-derived substituent 
attached to the exocyclic amino group has been reported [15]. 
In the course of our systematic investigations to synthetically access azadipeptide nitriles [3] we 
also converted an N,N’-unsubstituted hydrazide derived from phenylalanine with cyanogen bromide. 
Herein, the obtained product and its crystal structure will be described. 
2. Results and Discussion 
The synthesis followed the scheme outlined in Figure 1. Z-protected phenylalanine hydrazide (1), 
which was prepared as published [3], was reacted with cyanogen bromide using sodium acetate and 
methanol as solvent. The obtained crude product was purified by recrystallization from a mixture of 
petroleum ether and ethyl acetate to obtain crystals proved to be suitable for structure analysis. 
Figure 1. Synthesis of 2-amino-1,3,4-oxadiazole 2. 
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Data characterizing the crystals as well as parameters for data collection and structure refinement 
can be found in Table 1. The asymmetric unit consists of one molecule whose structure is shown in 
Figure 2. 
Table 1. Crystal data and parameters for structure refinement of 2. 
Parameter Value 
Empirical formula C18H18N4O3 
Formula weight 338.36 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21 (No. 4) 
Unit cell dimensions 
a = 9.8152(2) Å  
b = 9.6305(2) Å β = 116.785(1)  
c = 9.8465(2) Å 
Volume 830.88(3) Å3 
Z 2 
Density (calcd.) 1.352 g/cm3 
Absorption coefficient 0.095 mm−1 
F(000) 356 
Crystal size 0.30 × 0.20 × 0.10 mm3 
θmax. for data collection 27.5° 
Limiting indices −12  h  12, −12  k  12, −12  l  12 
Reflections collected/unique 15066/3795 [R(int) = 0.034] 
Completeness to θ = 25.00 99.6% 
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data/restraints/parameters 3795/4/235 
Goodness-of-fit on F2 0.985 
Final R indices [I > 2σ(I)] R1 = 0.029, wR2 = 0.061 
R indices (all data) R1 = 0.034, wR2 = 0.062 
Absolute structure parameter x = −0.1(6) (Flack’s x-parameter [16]); y = 0.0(5) (Hooft’s y-parameter [17]) 
Largest diff. peak and hole 0.116 and −0.193 e A−3 
Figure 2. Molecular structure of 2 as represented by the asymmetric unit. Atoms are 
represented by thermal ellipsoids at the 50% probability level. 
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The compound crystallized in the space group P21, which is one of the 65 Sohncke space groups 
characterized by containing only rotation or screw axes as symmetry elements. This fact combined 
with the observed optical rotation of the compound in solution indicates that only one enantiomer is 
present in the crystal structure [18,19]. The absolute configuration could not be determined by 
anomalous dispersion effects in the diffraction measurement on the crystal due to the absence of  
atoms heavier than oxygen. However, as the complete inversion of the configuration at the 
phenylalanine-derived Cα atom is highly unlikely, it can be concluded that the configuration at  
atom C9 is S. This indicates that all synthetic transformations leading to compound 2 starting  
from enantiopure Z-protected L-phenylalanine proceed without racemization at the Cα atom. The  
1,3,4-oxadiazole ring is completely planar, which is in accordance with the aromatic character of this 
heterocycle. The bond angles for the five-membered ring and the corresponding bond lengths are 
shown in Table 2. The length of the C18-N4 bond is with 1.345 Å similar to the nitrogen-carbon 
distance observed in other arylamines [20] and indicates the overlap of the nitrogens lone electron pair 
with the electron-deficient hetarene. 
Table 2. Bond angles and lengths for the 2-amino-1,3,4-oxadiazole moiety of 2. 
Internal angle Value (°) Bond Interatomic distance (Å) 
C17-N2-N3 106.4(1) C17-N2 1.282(1) 
N2-N3-C18 105.5(1) N2-N3 1.424(1) 
N3-C18-O3 113.2(1) N3-C18 1.294(2) 
C18-O3-C17 102.3(1) C18-O3 1.360(1) 
O3-C17-N2 112.6(1) O3-C17 1.376(1) 
– – C18-N4 1.345(2) 
Three types of intermolecular hydrogen bond contacts could be identified in the crystal structure 
(Figure 3). Two of them involve the exocyclic amino group (N4) as two-fold hydrogen bond donor 
forming contacts to the carbonyl oxygen (O1) of one neighboring molecule and one of the ring 
nitrogen atoms (N2). A further hydrogen bond contact is formed between the other ring nitrogen atom 
(N3) that is acting as acceptor towards the NH bond (N1) of the carbamate moiety. The atomic 
distances and geometries of the three hydrogen bonds are listed in Table 3. The observation that both 
ring nitrogens are acting as hydrogen bond acceptors whereas the ring oxygen does not is in agreement 
with quantum chemical calculations that assign a strong acceptor capacity to the nitrogen atoms of 
1,3,4-oxadiazoles [9]. 
A hydrogen bond pattern similar to the one observed in the crystal structure of compound 2 has 
been suggested for the complex of 5-(4-nitrophenyl)-N-(4-methoxyphenyl)-1,3,4-oxadiazol-2-amine 
and glycogen synthase kinase 3β (GSK-3β) on the basis of molecular docking studies [21]. The results 
of this in silico study provided evidence for the formation of hydrogen bond contacts between the 
1,3,4-oxadiazol-2-amine moiety and the backbone of two consecutive amino acids in the hinge region 
of the ATP binding pocket of GSK-3β, Tyr134 and Val135. Both ring nitrogens presumably act as 
hydrogen bond acceptors towards the NH bonds of both amino acids while the exocyclic NH is 
accepted by the carbonyl oxygen of Val 135. The fact that the hydrogen bond pattern observed in here 
matches the one predicted for the enzyme-inhibitor complex emphasizes the 2-amino-1,3,4-oxadiazole 
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system as a structural element privileged for interaction with the ATP binding pockets of kinases and 
other proteins [22]. 
Figure 3. Crystal packing of 2. Dashed lines are indicating hydrogen bond contacts. Lattice 
constants are shown in different colors: (a) red; (b) green; (c) blue. 
 
Table 3. Interatomic distances and geometries for hydrogen bonds in the crystal structure of 2. 
D-H...A d(D-H) (Å) d(H...A) (Å) d(D...A) (Å)  (D-HA) (°) 
N(1)-H(1)...N(3) i 0.87(1) 2.04(1) 2.90(1) 168(1) 
N(4)-H(4A)...O(1) ii 0.88(1) 2.32(1) 3.17(1) 164(1) 
N(4)-H(4B)...N(2) iii 0.89(1) 2.55(1) 3.40(2) 161(1) 
Symmetry codes for generation of equivalent atoms: i: −x + 1, y − 1/2, −z + 1; ii: − x+ 1, y + 1/2, −z;  
iii: −x + 1, y + 1/2, −z + 1. 
Considering the packing of the molecules in the crystal, interactions between the phenyl rings of the 
carbobenzoxy and phenylalanine-derived moieties of adjacent molecules become obvious. These 
interactions can be interpreted as aromatic T-shaped or edge-to-face contacts as indicated by 
alternating centroid-centroid distances of 5.247 Å and 4.777 Å (Figure 4). The angle of inclination 
between the planes of the adjacent phenyl rings is 74.83°, corresponding to a deviation of 25.17° from 
the ideal perpendicular orientation [23,24]. This suggests that the intermolecular forces in the crystal 
are strongly determined by aromatic interactions originating from the two phenyl rings of the 
compound in addition to hydrogen bond contacts. 
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Figure 4. Aromatic interactions in the crystal packing of 2 illustrated by centroid-centroid 
distances in Å. 
 
3. Experimental Section  
Melting points were determined on a Büchi 510 oil bath apparatus and are not corrected. Thin layer 
chromatography was performed on Merck aluminum sheets. Optical rotations were determined on a 
Perkin-Elmer 241 polarimeter. 1H NMR spectra (500 MHz) and 13C NMR spectra (125 MHz) were 
recorded on a Bruker Avance 500 spectrometer. Mass spectra were obtained on an A.E.I. MS-50 
spectrometer (EI, 70 eV).  
3.1. Synthesis of Benzyl [(1S)-1-(5-amino-1,3,4-oxadiazol-2-yl)-2-phenylethyl]carbamate (2) 
To a solution of N-(benzyloxycarbonyl)-phenylalanine hydrazide (1; prepared as published in [3]; 
0.30 g, 0.96 mmol) in methanol (10 mL) and THF (5 mL), sodium acetate (0.22 g,  
2.69 mmol) and cyanogen bromide (0.11 g, 1.10 mmol) were added as solids. Caution: cyanogen 
bromide is highly toxic and may cause death by inhalation. It should be handled in a well ventilated 
hood only with the utmost care. After stirring for 8 h at room temperature the solvent was removed in 
vacuo and the obtained residue was washed with water, dried in a desiccator over P4O10 and 
recrystallized from petroleum ether/ethyl acetate to afford 2 (0.19 g, 58%) as colorless crystals.  
m.p. 142–144 °C; [α]D20 = −41.5° (c = 1.88, dioxane); 1H NMR (500 MHz, CDCl3): δ in ppm = 3.14 
(dd, 2J = 12.6 Hz, 3J = 6.9 Hz, 1H, C10HH); 3.25 (dd, 2J = 13.9 Hz, 3J = 6.3 Hz, 1H, C10HH);  
5.03 (d, 2J = 12.3 Hz, 1H, C2HH); 5.07 (d, 2J = 12.3 Hz, 1H, C2HH); 5.13–5.20 (m, 1H, C9H);  
5.31 (br s, 2H, N4H2); 5.40 (d, 3J = 8.9 Hz, 1H, N1H); 7.09–7.13 (m, 2H, C16H/C12H); 7.18–7.34  
(m, 8H, Harom); 13C NMR (125 MHz, CDCl3): δ in ppm = 39.15 (C10); 48.56 (C9); 67.17 (C2);  
127.21 (C14); 128.05 (C4/C8); 128.22 (C6); 128.52, 128.68, 129.32 (C12/C16, C13/C15, C5/C7); 
135.37, 136.02 (C11, C3); 155.54 (C1); 159.98 (C18); 163.10 (C17); MS (EI) m/z (%): 338 (10, M+); 
247 (18, [M-C7H7]+); 230 (15, [M-C7H7-NH3]+); 203 (10, [M-BnOCO]+); 91 (100, C7H7+). 
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3.2. Crystal Structure Determination 
The X-ray crystal structure of compound 2 was determined with a Nonius KappaCCD 
diffractometer at a temperature of 123 K and a wavelength of 0.71073 Å (Mo-Kα radiation). The 
structure was solved by direct methods using the program SHELXS-97, refinement was done  
with SHELXL-97 (both programs are part of SHELX-97 [25]). Non-hydrogen atoms were refined 
anisotropically and hydrogens with a riding model. Exceptionally, hydrogen atoms bound to nitrogen 
were refined freely. The absolute configuration has not been established by anomalous dispersion 
effects in diffraction measurement on the crystal. The enantiomer has been assigned by reference to an 
unchanging chiral centre in the synthetic procedure. Structures were visualized and evaluated using 
Mercury 3.0, The Cambridge Crystallographic Data Centre [26]. Errors of presented bond lengths and 
angles are given in brackets and refer to the last decimal place. 
Crystallographic data (excluding structure factors) for the structure reported in this work have been 
deposited with the Cambridge Crystallographic Data Centre as supplementary publication no. CCDC 
884101 (2). Copies of the data can be obtained free of charge on application to The Director,  
CCDC, 12 Union Road, Cambridge DB2 1EZ, UK. 
4. Conclusions  
The title compound 2 was prepared and its molecular structure was deduced from its X-ray 
diffraction pattern. This unequivocally confirms the non-existence of N’-cyanohydrazides bearing 
hydrogen atoms at both nitrogens due to spontaneous cyclization to 2-amino-1,3,4-oxadiazoles. To the 
best of our knowledge, a crystal structure of an amino acid-derived 2-amino-1,3,4-oxadiazole has not 
been reported before. 
An extensive network of hydrogen bonds as well as edge-to-face interactions could be identified in 
the crystal packing. The observed hydrogen bond pattern involving the heterocycle as well the 
exocyclic amino group supports the importance of such moieties for the design of biologically active 
molecules able to interact with the ATP-binding pockets of some proteins.  
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